Front-line ibrutinib treatment is associated with longer time to next treatment, net total cost reduction, and lower healthcare resource utilization compared to chemoimmunotherapy in patients with chronic lymphocytic leukemia Meeting Abstract
| Authors: | Wang, S.; Emond, B.; Romdhani, H.; Lefebvre, P.; Sundaram, M.; Mato, A. R. |
| Abstract Title: | Front-line ibrutinib treatment is associated with longer time to next treatment, net total cost reduction, and lower healthcare resource utilization compared to chemoimmunotherapy in patients with chronic lymphocytic leukemia |
| Meeting Title: | 60th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 132 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2018 Dec 1-4 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2018-11-29 |
| Language: | English |
| ACCESSION: | WOS:000454837606279 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood-2018-99-116473 |
| Notes: | Meeting Abstract: 2306 -- Source: Wos |
